Proceedings of the 2023 Viral Clearance Symposium, Session 8: Cell Banks, Advanced Technologies (ATMPs, NGS)

References

1. 1.↵
   International Conference for Harmonisation. Harmonised Tripartate Guideline Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH: Geneva, 1999.
2. 2.↵
   Council of Europe, Tests for Extraneous Agents in Viral Vaccines for Human Use, Chapter 2.6.16. In European Pharmacopoeia (Ph. Eur.), Version 9.3. Council of Europe: Strasbourg, France, 2017.
3. 3.↵
   U.S. Food and Drug Administration, Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2010.
4. 4.↵
   1. Mallet L.,
   2. Gisonni-Lex L.

   Need for New Technologies for Detection of Adventitious Agents in Vaccines and Other Biological Products. PDA J. Pharm. Sci. Technol. 2014, 68 (6), 556–562.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Khan A. S.,
   2. Benetti L.,
   3. Blumel J.,
   4. Deforce D.,
   5. Egan W. M.,
   6. Knezevic I.,
   7. Krause P. R.,
   8. Mallet L.,
   9. Mayer D.,
   10. Minor P. D.,
   11. Neels P.,
   12. Wang G.

   Report of the International Conference on Next Generation Sequencing for Adventitious Virus Detection in Biologicals. Biologicals 2018, 55, 1–16.

   OpenUrl
6. 6.↵
   1. Khan A. S.,
   2. Vacante D. A.,
   3. Cassart J.-P.,
   4. Ng S. H.,
   5. Lambert C.,
   6. Charlebois R. L.,
   7. King K. E.

   Advanced Virus Detection Technologies Interest Group (AVDTIG): Efforts on High Throughput Sequencing (HTS) for Virus Detection. PDA J. Pharm. Sci. Technol. 2016, 70 (6), 591–595.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Victoria J. G.,
   2. Wang C.,
   3. Jones M. S.,
   4. Jaing C.,
   5. McLoughlin K.,
   6. Gardner S.,
   7. Delwart E. L.

   Viral Nucleic Acids in Live-Attenuated Vaccines: Detection of Minority Variants and an Adventitious Virus. J. Virol. 2010, 84 (12), 6033–6040.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Walsh G.

   Biopharmaceutical Benchmarks 2014. Nat. Biotechnol. 2014, 32 (10), 992–1000.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Brussel A.,
   2. Brack K.,
   3. Muth E.,
   4. Zirwes R.,
   5. Cheval J.,
   6. Hebert C.,
   7. Charpin J.-M.,
   8. Marinaci A.,
   9. Flan B.,
   10. Ruppach H.,
   11. Beurdeley P.,
   12. Eloit M.

   Use of a New RNA Next Generation Sequencing Approach for the Specific Detection of Virus Infection in Cells. Biologicals 2019, 59, 29–36.

   OpenUrlCrossRef
10. 10.↵
    1. Ma H.,
    2. Nandakumar S.,
    3. Bae E. H.,
    4. Chin P.-J.,
    5. Khan A. S.

    The Spodoptera frugiperda Sf9 Cell Line is a Heterogeneous Population of Rhabdovirus-Infected and Virus-Negative Cells: Isolation and Characterization of Cell Clones Containing Rhabdovirus X-Gene Variants and Virus-Negative Cell Clones. Virology 2019, 536, 125–133.

    OpenUrl
11. 11.↵
    1. Gombold J.,
    2. Karakasidis S.,
    3. Niksa P.,
    4. Podczasy J.,
    5. Neumann K.,
    6. Richardson J.,
    7. Sane N.,
    8. Johnson-Leva R.,
    9. Randolph V.,
    10. Sadoff J.,
    11. Minor P.,
    12. Schmidt A.,
    13. Duncan P.,
    14. Sheets R. L.

    Systematic Evaluation of In Vitro and In Vivo Adventitious Virus Assays for the Detection of Viral Contamination of Cell Banks and Biological Products. Vaccine 2014, 32 (24), 2916–2926.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Barone P. W.,
    2. Keumurian F. J.,
    3. Neufeld C.,
    4. Koenigsberg A.,
    5. Kiss R.,
    6. Leung J.,
    7. Wiebe M.,
    8. Ait-Belkacem R.,
    9. Azimpour Tabrizi C.,
    10. Barbirato C.,
    11. Beurdeley P.,
    12. Brussel A.,
    13. Cassart J.-P.,
    14. Cote C.,
    15. Deneyer N.,
    16. Dheenadhayalan V.,
    17. Diaz L.,
    18. Geiselhoeringer A.,
    19. Gilleece M. M.,
    20. Goldmann J.,
    21. Hickman D.,
    22. Holden A.,
    23. Keiner B.,
    24. Kopp M.,
    25. Kreil T. R.,
    26. Lambert C.,
    27. Logvinoff C.,
    28. Michaels B.,
    29. Modrof J.,
    30. Mullan B.,
    31. Mullberg J.,
    32. Murphy M.,
    33. O'Donnell S.,
    34. Peña J.,
    35. Ruffing M.,
    36. Ruppach H.,
    37. Salehi N.,
    38. Shaid S.,
    39. Silva L.,
    40. Snyder R.,
    41. Spedito-Jovial M.,
    42. Vandeputte O.,
    43. Westrek B.,
    44. Yang B.,
    45. Yang P.,
    46. Springs S. L.

    Historical Evaluation of the In Vivo Adventitious Virus Test and Its Potential for Replacement with Next Generation Sequencing (NGS). Biologicals 2023, 81, 101661.

    OpenUrl
13. 13.↵
    International Conference for Harmonisation. ICH Guideline Q2(R2): Validation of Analytical Procedures, EMA/CHMP/ICH/82072/2006, ICH: Geneva, 2024.
14. 14.↵
    U.S. Food and Drug Administration. 21 CFR Part 11: Guidance for Industry Part 11, Electronic Records; Electronic Signatures—Scope and Application, U.S. Department of Health and Human Services. Government Publishing Office: Washington, D.C., 2003.
15. 15.↵
    European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 11: Computerised Systems. European Commission: Brussels, 2011.
16. 16.↵
    Council of Europe, Cell Substrates for the Production of Vaccines for Human Use, Chapter 5.2.3. In European Pharmacopoeia, Version 9:0 and updated Version 9.3, Council of Europe: Strasbourg, France, 2017.
17. 17.↵
    International Conference for Harmonisation. Harmonised Tripartate Guideline Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin—Step 4, Final Version. ICH: Geneva, 2023.
18. 18.↵
    1. Wieser A.,
    2. Modrof J.,
    3. Kreil T. R.

    Protection of Biomanufacturing Processes from Virus Contamination through Upstream Virus Filtration of Cell Culture Media. Biotechnol. Bioeng. 2023, 120 (10), 2917–2924.

    OpenUrl